Kymera Therapeutics is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. Powered by a proprietary predictive modeling capability and a game-changing integrated degradation platform, Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/30/17 | $30,000,000 | Series A |
Amgen Business Development Atlas Venture  Lilly Ventures | undisclosed |
| 11/13/18 | $65,000,000 | Series B |
6 Dimensions Capital AJU IB Investment Hatteras Venture Partners MRL Ventures Fund Pfizer Venture Investments Sanofi Ventures | undisclosed |
| 03/12/20 | $102,000,000 | Series C |
Bain Capital Life Sciences Biotechnology Value Fund BlackRock Janus Henderson Investors Redmile Group Rock Springs Capital Wellington Management Company | undisclosed |
